$0.925
+0.017 (+1.79%)收盤時
價格預測
在 App 中開啟以解鎖更長週期的預測。
GDTC 相似圖表分析預測
Alphio's GDTC stock price prediction model matches the current CytoMed Therapeutics Ltd tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $0.94 (+1.76%). The 1-week path is $0.98 (+6.43%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
該買進 CytoMed Therapeutics Ltd 股票嗎?
CytoMed Therapeutics Ltd (GDTC) is not a good buy right now due to its significant downward trends and poor financial metrics. The current price is $0.92, which is down 33.81% year-to-date and 54.11% over the past year. Additionally, the stock has a negative P/E ratio of -1.91 and a forward P/E of 0, indicating a lack of profitability and future earnings potential. The RSI is at 46.19, suggesting the stock is neither overbought nor oversold, but the overall trend is negative. The main risk is the 5-day change of -10.68%, indicating a recent sharp decline in value.
GDTC 股價於 Tuesday 收在 $0.93,此前上漲 +1.79%
CytoMed Therapeutics Ltd (GDTC) last closed at $0.925, gaining +1.79%. These facts feed the 1-day and 1-week GDTC price prediction above.
預測驅動因素
CytoMed Therapeutics Ltd(GDTC)的預測驅動因素綜合了相似的圖表形態、季節性與移動平均線。
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bullish
SMA 200
Bearish
相似圖表形態
近期走勢與 GDTC 最接近的股票,依相似度排序。
GDTC 季節性分析
Historically the probability of a positive September return for GDTC is 0.00%. January offers the highest probability of a positive month at 4.92%, while February is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。